Voyager Therapeutics (VYGR) Cash from Financing Activities (2014 - 2026)

Voyager Therapeutics has disclosed Cash from Financing Activities across 13 years of filings, most recently posting $3.3 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $3.3 million, up 3963.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (up 227.64% YoY), and the FY2025 annual result was $816000.0, down 99.28% from the prior year.
• Cash from Financing Activities came in at $3.3 million for Q1 2026 at Voyager Therapeutics, up from $136000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $112.9 million in Q1 2024 to a low of $12000.0 in Q1 2022.
• The 5-year median for Cash from Financing Activities is $460000.0 (2023), against an average of $9.0 million.
• Across the five-year window, Cash from Financing Activities jumped 260783.33% in 2023 and tumbled 99.93% in 2025, its largest moves.
• Voyager Therapeutics' Cash from Financing Activities stood at $276000.0 in 2022, then jumped by 66.67% to $460000.0 in 2023, then advanced by 24.78% to $574000.0 in 2024, then plunged by 76.31% to $136000.0 in 2025, then jumped by 2350.0% to $3.3 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.3 million (Q1 2026), $136000.0 (Q4 2025), and $85000.0 (Q3 2025), per Business Quant data.